Rilonacept: Difference between revisions
From IDWiki
(Created page with "* IL-1 inhibitor * Dimeric fusion protein with the extracellular component of IL-1 receptor fused to the Fc portion of IgG1 ** Binds circulating IL-1α and IL-1β * Indication...") |
mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
* Indications include cryopyrin-associated periodic syndromes ([[familial cold autoinflammatory syndrome]] and [[Muckle-Wells syndrome]]) |
* Indications include cryopyrin-associated periodic syndromes ([[familial cold autoinflammatory syndrome]] and [[Muckle-Wells syndrome]]) |
||
* Infectious complications include most commonly [[Upper respiratory tract infection|upper respiratory tract infections]], but also [[pneumococcus]], [[meningitis]], [[NTM]], and [[bronchitis]] |
* Infectious complications include most commonly [[Upper respiratory tract infection|upper respiratory tract infections]], but also [[pneumococcus]], [[meningitis]], [[NTM]], and [[bronchitis]] |
||
| ⚫ | |||
| ⚫ | |||
Latest revision as of 01:17, 17 March 2022
- IL-1 inhibitor
- Dimeric fusion protein with the extracellular component of IL-1 receptor fused to the Fc portion of IgG1
- Binds circulating IL-1α and IL-1β
- Indications include cryopyrin-associated periodic syndromes (familial cold autoinflammatory syndrome and Muckle-Wells syndrome)
- Infectious complications include most commonly upper respiratory tract infections, but also pneumococcus, meningitis, NTM, and bronchitis
